Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ponatinib for Relapse Prevention in FLT3-ITD AML
NCT03690115Phase 2Completed
- Sponsor
- Centre Hospitalier de Versailles
- Start
- Dec 2019
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ponatinib in acute myeloid leukemia (AML), sponsored by Centre Hospitalier de Versailles. Primary endpoint: Relapse incidence at 2 years from transplant. Started Dec 2019; status: completed.
02
Drugs
ponatinib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03690115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03690115.